Technology including intellectual property and knowhow, developed by the UK Gene Therapy Consortium, made up of researchers at Imperial College London, the University of Oxford and Edinburgh University has been licensed to Boehringer Ingelheim in a continuation of a licence agreement first announced in 2018.
Accelerated development of a potential treatment for cystic fibrosis
Sectors: Medical research, Pharmaceuticals
Industries: Biotechnology
Related technologies
A novel targeted drug delivery system
Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots. Find out more
A novel targeted drug delivery system
A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics Find out more
Aptamer-based multiplex screening platform
A fully flexible, scalable and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific sequences along the backbone of a double-stranded DNA carrier. Find out more
Related news
Accelerated development of a potential treatment for cystic fibrosis
The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim. Find out more
Related events
Imperial.tech.pitch events – learn more and sign up
Event date - October 1, 2023
Learn about our programme of events and sign up to be alerted for future events Find out more
Sign up for updates
Sign up for monthly technology alerts via email, and find other ways to connect with us.